Blood Substitutes

Clearance Received for Phase II Human Trials in Canada

Published in Cancer Weekly, March 10th, 1997

Hemosol Inc., Toronto, Ontario, Canada, announced that clearance has been received from the Health Protection Branch of Health Canada to begin Phase II human clinical trials of Hemolink.

Hemolink is a red blood cell substitute product. Alun Davies, Hemosol, said that the initial stage of the trials was planned for performance in a Toronto-area hospital. "This is a watershed event for us and particularly satisfying since Hemolink is the first hemoglobin-based oxygen carrier to be approved for Phase II trials in Canada by regulatory authorities," said Davies.

"Our continuing animal studies have confirmed our belief that Hemolink has a clinical...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1997-03-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry